Five notes:
1. Despite a slowdown in 2024, healthcare M&A activity remained nearly 70% higher than pre-pandemic levels. There were 1,373 healthcare deals in 2024, 1,506 in 2023, 1,708 in 2022, 1,525 in 2021, 814 in 2020 and 828 in 2019.
2. Deals worth more than $5 billion were subdued compared to recent years, with only one such deal completed in 2024. Healthcare deals were collectively worth $69 billion in 2024, $63 billion in 2023, $101 billion in 2022, $197 billion in 2021, $56 billion in 2020 and $88 billion in 2019.
3. A significant amount of available capital, possible interest rate cuts, lengthening hold periods and the pro-business stance expected from the Trump administration is fueling optimism for increased M&A in 2025. The incoming administration’s stance on antitrust enforcement, provider reimbursement, and broader regulatory issues — ranging from staffing mandates to Medicaid funding and value-based care programs — will shape investor strategies.
4. Large health systems are maintaining their focus on strategic rationalization of their portfolios and a return to pre-COVID operating margins, while payers continue to focus on vertical integration and geographic expansion.
5. Those involved with M&A should embrace flexible deal structures, focus on value creation through AI-driven solutions, and capitalize on opportunities in provider consolidation, employer-sponsored insurance programs, and tech-enabled innovations supporting value-based care.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
